431 related articles for article (PubMed ID: 16575015)
21. The epothilones: how pharmacology relates to clinical utility.
Michaud LB
Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
[TBL] [Abstract][Full Text] [Related]
22. Assessing the utility of in vitro microtubule assays for studying mechanisms of peripheral neuropathy with the microtubule inhibitor class of cancer chemotherapy.
Genualdi C; Feinstein SC; Wilson L; Jordan MA; Stagg NJ
Chem Biol Interact; 2020 Jan; 315():108906. PubMed ID: 31760042
[TBL] [Abstract][Full Text] [Related]
23. Oxaliplatin-associated neuropathy: a review.
Cersosimo RJ
Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
[TBL] [Abstract][Full Text] [Related]
24. Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms.
Kautio AL; Haanpää M; Leminen A; Kalso E; Kautiainen H; Saarto T
Anticancer Res; 2009 Jul; 29(7):2601-6. PubMed ID: 19596934
[TBL] [Abstract][Full Text] [Related]
25. [Clinical features of paclitaxel-induced peripheral neuropathy and role of Gosya-jinki-gan].
Yamamoto T; Murai T; Ueda M; Katsuura M; Oishi M; Miwa Y; Okamoto Y; Uejima E; Taguchi T; Noguchi S; Kurokawa N
Gan To Kagaku Ryoho; 2009 Jan; 36(1):89-92. PubMed ID: 19151569
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies.
Beijers AJ; Jongen JL; Vreugdenhil G
Neth J Med; 2012 Jan; 70(1):18-25. PubMed ID: 22271810
[TBL] [Abstract][Full Text] [Related]
27. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation.
Argyriou AA; Chroni E; Koutras A; Iconomou G; Papapetropoulos S; Polychronopoulos P; Kalofonos HP
J Pain Symptom Manage; 2006 Sep; 32(3):237-44. PubMed ID: 16939848
[TBL] [Abstract][Full Text] [Related]
28. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
Cigler T; Vahdat L
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of efficacy and safety of adjuvant analgesics for peripheral neuropathy induced by cancer chemotherapy in digestive cancer patients-a pilot study].
Yano T; Yamane H; Fukuoka R; Ninomiya T; Umemura S; Suzuki S; Saeki H; Hanaoka T; Katou T; Itoh K; Fujita T; Kamei H
Gan To Kagaku Ryoho; 2009 Jan; 36(1):83-7. PubMed ID: 19151568
[TBL] [Abstract][Full Text] [Related]
30. Peripheral neuropathy: experimental findings, clinical approaches.
J Support Oncol; 2007 Feb; 5(2):61-3. PubMed ID: 17354318
[No Abstract] [Full Text] [Related]
31. Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.
Morris PG; Fornier MN
Clin Adv Hematol Oncol; 2009 Feb; 7(2):115-22. PubMed ID: 19367253
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy-induced peripheral neuropathy: prevention and treatment.
Pachman DR; Barton DL; Watson JC; Loprinzi CL
Clin Pharmacol Ther; 2011 Sep; 90(3):377-87. PubMed ID: 21814197
[TBL] [Abstract][Full Text] [Related]
33. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity.
Callizot N; Andriambeloson E; Glass J; Revel M; Ferro P; Cirillo R; Vitte PA; Dreano M
Cancer Chemother Pharmacol; 2008 Nov; 62(6):995-1007. PubMed ID: 18270703
[TBL] [Abstract][Full Text] [Related]
35. A pilot study on the relation between cisplatin neuropathy and vitamin E.
Bove L; Picardo M; Maresca V; Jandolo B; Pace A
J Exp Clin Cancer Res; 2001 Jun; 20(2):277-80. PubMed ID: 11484987
[TBL] [Abstract][Full Text] [Related]
36. [Chemotherapy-induced peripheral neuropathy: an unresolved issue].
Velasco R; Bruna J
Neurologia; 2010 Mar; 25(2):116-31. PubMed ID: 20487712
[TBL] [Abstract][Full Text] [Related]
37. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.
LaPointe NE; Morfini G; Brady ST; Feinstein SC; Wilson L; Jordan MA
Neurotoxicology; 2013 Jul; 37():231-9. PubMed ID: 23711742
[TBL] [Abstract][Full Text] [Related]
38. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
39. [A retrospective analysis of adverse events based on a dose and a schedule in patients who underwent paclitaxel- containing chemotherapy].
Yoshimura T; Hirade K; Iihara H; Ishihara M; Komori Y; Okayasu S; Matsuura K; Yasuda T; Itoh Y
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1721-6. PubMed ID: 18931576
[TBL] [Abstract][Full Text] [Related]
40. Peripheral nerve damage associated with administration of taxanes in patients with cancer.
Argyriou AA; Koltzenburg M; Polychronopoulos P; Papapetropoulos S; Kalofonos HP
Crit Rev Oncol Hematol; 2008 Jun; 66(3):218-28. PubMed ID: 18329278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
